Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2009

01.05.2009 | Melanomas

Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients

verfasst von: Hidde M. Kroon, MD, Marc Moncrieff, MD, FCRS, Peter C. A. Kam, MD, FRCA, FANZCA, John F. Thompson, MD, FRACS, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Isolated limb infusion (ILI) with cytotoxic drugs is a low-flow isolated limb perfusion (ILP) performed via percutaneous catheters without oxygenation to treat metastatic melanoma confined to a limb. Response rates and duration of response following ILI are similar to those after ILP. Previously we have shown that more significant limb toxicity is not associated with a higher response rate or improved patient outcome. In this study we sought to determine factors predicting toxicity following ILI.

Methods

From our prospective database 185 patients with advanced metastatic melanoma of the limb treated with a single ILI between 1992 and 2007 were identified. In all patients a cytotoxic combination of melphalan and actinomycin D was used. Drug circulation time was 20–30 min under mild hyperthermic conditions (38–39°C). Limb toxicity was assessed using the Wieberdink scale.

Results

The average patient age was 74 years (range 29–93 years) and 62% were female. Most patients (134/185) had MD Anderson stage III disease (satellites and in-transit metastases). Toxicity grade I (no reaction) occurred in 3 patients, grade II (slight erythema and edema) in 105 patients, grade III (considerable erythema and edema ± blistering) in 72 patients, and grade IV (threatened or actual compartment syndrome) in 5 patients. No patient developed grade V toxicity (requiring amputation). On univariate analysis high peak and high final melphalan concentrations were found to be predictive factors for grade III/IV limb toxicity as well as the area under the curve of the melphalan concentration. Surprisingly, a greater rise in the CO2 level during the procedure was associated with lower toxicity in the univariate analysis. Increased serum creatine phosphokinase (CK) postoperatively was related to higher toxicity score. In the multivariate analysis high final melphalan concentration and shorter tourniquet time were independent predictive risk factors for developing grade III/IV limb toxicity.

Conclusions

ILI is a safe alternative to the more invasive and laborious ILP technique to treat melanoma confined to a limb. Regional acute toxicity following ILI is mild to moderate in most patients. Based on the predictive factors found in this series, altering melphalan dose and tourniquet time may allow further reductions in post-ILI toxicity without compromising effectiveness.
Literatur
1.
Zurück zum Zitat Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996;83:1319–28.PubMedCrossRef Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996;83:1319–28.PubMedCrossRef
2.
Zurück zum Zitat Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion for melanoma patients: a review of its indications and the role of tumor necrosis factor-α. Eur J Surg Oncol. 2006;32:371–80.PubMedCrossRef Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion for melanoma patients: a review of its indications and the role of tumor necrosis factor-α. Eur J Surg Oncol. 2006;32:371–80.PubMedCrossRef
3.
Zurück zum Zitat Sanki A, Kam PCA, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma. Ann Surg. 2007;4:591–6.CrossRef Sanki A, Kam PCA, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma. Ann Surg. 2007;4:591–6.CrossRef
4.
Zurück zum Zitat Thompson JF, De Wilt JHW. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol. 2001;8:564–5.PubMedCrossRef Thompson JF, De Wilt JHW. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol. 2001;8:564–5.PubMedCrossRef
5.
Zurück zum Zitat Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol. 1998;14:224–31.PubMedCrossRef Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol. 1998;14:224–31.PubMedCrossRef
6.
Zurück zum Zitat Thompson JF, Kam PCA, de Wilt JHW, Lindnér P. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of Melanoma. London: Martin Dunitz; 2004. p. 429–37. Thompson JF, Kam PCA, de Wilt JHW, Lindnér P. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of Melanoma. London: Martin Dunitz; 2004. p. 429–37.
7.
Zurück zum Zitat Lindnér P, Doubrovsky A, Kam PCA, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9:127–36.PubMed Lindnér P, Doubrovsky A, Kam PCA, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9:127–36.PubMed
8.
Zurück zum Zitat Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13:1123–9.PubMedCrossRef Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13:1123–9.PubMedCrossRef
9.
Zurück zum Zitat Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15:3003–13.PubMedCrossRef Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15:3003–13.PubMedCrossRef
10.
Zurück zum Zitat Vrouenraets BC, Eggermont AMM, Hart AAM, Klaase JM, van Geel AN, Nieweg OE, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-α versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27:390–5.PubMedCrossRef Vrouenraets BC, Eggermont AMM, Hart AAM, Klaase JM, van Geel AN, Nieweg OE, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-α versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27:390–5.PubMedCrossRef
11.
Zurück zum Zitat Thompson JF, Eksborg S, Kam PCA, Ingvar C, Yau DF, Lai DT, et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res. 1996;6:267–71.PubMedCrossRef Thompson JF, Eksborg S, Kam PCA, Ingvar C, Yau DF, Lai DT, et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res. 1996;6:267–71.PubMedCrossRef
12.
Zurück zum Zitat Vrouenraets BC, Hart GA, Eggermont AM, Klaase JM, van Geel BN, Nieweg OE, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999;188:522–30.PubMedCrossRef Vrouenraets BC, Hart GA, Eggermont AM, Klaase JM, van Geel BN, Nieweg OE, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999;188:522–30.PubMedCrossRef
13.
Zurück zum Zitat Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905–10.PubMedCrossRef Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905–10.PubMedCrossRef
14.
Zurück zum Zitat Lindnér P, Thompson JF, De Wilt JH, Colman M, Kam PC. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol. 2004;30:433–9.PubMedCrossRef Lindnér P, Thompson JF, De Wilt JH, Colman M, Kam PC. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol. 2004;30:433–9.PubMedCrossRef
15.
Zurück zum Zitat Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg. 2001;44:189–92.PubMed Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg. 2001;44:189–92.PubMed
16.
Zurück zum Zitat Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–92. Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–92.
17.
Zurück zum Zitat Thompson JF, Kam PCA, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238- 47.PubMedCrossRef Thompson JF, Kam PCA, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238- 47.PubMedCrossRef
18.
Zurück zum Zitat Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol. 2004;1:88:1–3.CrossRef Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol. 2004;1:88:1–3.CrossRef
19.
Zurück zum Zitat Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132:903–7.PubMed Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132:903–7.PubMed
20.
Zurück zum Zitat Lai DT, Ingvar C, Thompson JF. The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat. 1993;1:36–9. Lai DT, Ingvar C, Thompson JF. The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat. 1993;1:36–9.
21.
Zurück zum Zitat Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, Hart AAM. Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg. 1994;167:618–20.PubMedCrossRef Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, Hart AAM. Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg. 1994;167:618–20.PubMedCrossRef
22.
Zurück zum Zitat Liénard D, Lejeune F, Autier Ph, Sales F, Ghanem G. Physiological and pharmacokinetics parameters in isolation perfusion of the limbs. In: Lejeune FJ, Chaudhuri PK, Das Gupta T, editors. Malignant Melanoma: Medical and Surgical Management . New York: McGraw-Hill; 1994. p. 241–8. Liénard D, Lejeune F, Autier Ph, Sales F, Ghanem G. Physiological and pharmacokinetics parameters in isolation perfusion of the limbs. In: Lejeune FJ, Chaudhuri PK, Das Gupta T, editors. Malignant Melanoma: Medical and Surgical Management . New York: McGraw-Hill; 1994. p. 241–8.
23.
Zurück zum Zitat Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50–60.CrossRef Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50–60.CrossRef
24.
Zurück zum Zitat Klaase JM, Kroon BBR, van Geel AN, van Wijk J, Franklin HR, Eggermont AMM, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg. 1994:178:564–72.PubMed Klaase JM, Kroon BBR, van Geel AN, van Wijk J, Franklin HR, Eggermont AMM, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg. 1994:178:564–72.PubMed
25.
Zurück zum Zitat World Health Organization. WHO Handbook for Reporting Results of Cancer Treatments (WHO Offset Publication No. 48). Geneva: World Health Organization; 1979. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatments (WHO Offset Publication No. 48). Geneva: World Health Organization; 1979.
26.
Zurück zum Zitat Vrouenraets BC, Kroon BB, Klaase JM, Nieweg OE, van Slooten GW, van Dongen JA. Severe acute regional toxicity after normothermic or “mild” hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res. 1995;5:425–31.PubMedCrossRef Vrouenraets BC, Kroon BB, Klaase JM, Nieweg OE, van Slooten GW, van Dongen JA. Severe acute regional toxicity after normothermic or “mild” hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res. 1995;5:425–31.PubMedCrossRef
27.
Zurück zum Zitat Vrouenraets BC, Klaase JM, Kroon BB, van Geel BN, Eggermont AM, Franklin HR. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg. 1995;130:43–7.PubMed Vrouenraets BC, Klaase JM, Kroon BB, van Geel BN, Eggermont AM, Franklin HR. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg. 1995;130:43–7.PubMed
28.
Zurück zum Zitat Klaase JM, Kroon BB, van Slooten GW, Benckhuijsen C. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Reg Cancer Treat. 1992;4:309–12. Klaase JM, Kroon BB, van Slooten GW, Benckhuijsen C. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Reg Cancer Treat. 1992;4:309–12.
29.
Zurück zum Zitat Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195–205.PubMedCrossRef Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195–205.PubMedCrossRef
30.
Zurück zum Zitat Scott RN, Blackie R, Kerr DJ, et al. Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In: Jakesz R, Rainer H, editors. Progress in Regional Cancer Therapy. Berlin-Heidelberg: Springer-Verlag; 1990. p. 195–200. Scott RN, Blackie R, Kerr DJ, et al. Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In: Jakesz R, Rainer H, editors. Progress in Regional Cancer Therapy. Berlin-Heidelberg: Springer-Verlag; 1990. p. 195–200.
31.
Zurück zum Zitat Klaase JM, Kroon BBR, Beijnen JH, van Slooten GW, van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70:151–3.PubMed Klaase JM, Kroon BBR, Beijnen JH, van Slooten GW, van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70:151–3.PubMed
32.
Zurück zum Zitat Roberts MS, Wu ZY, Siebert GA, Anissimov YF, Thompson JF, Smithers BM. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res. 2001;11:423–31.PubMedCrossRef Roberts MS, Wu ZY, Siebert GA, Anissimov YF, Thompson JF, Smithers BM. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res. 2001;11:423–31.PubMedCrossRef
33.
Zurück zum Zitat Thompson JF, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer. 2001;85:157–65.PubMedCrossRef Thompson JF, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer. 2001;85:157–65.PubMedCrossRef
34.
Zurück zum Zitat Roberts MS, Wu ZY, Siebert GA, Thompson JF, Smithers BM. Saturable dose–response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res. 2001;11:611–8.PubMedCrossRef Roberts MS, Wu ZY, Siebert GA, Thompson JF, Smithers BM. Saturable dose–response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res. 2001;11:611–8.PubMedCrossRef
35.
Zurück zum Zitat Beasley GM, Ross MI, Tyler DS. Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia. 2008;24:301–9.PubMedCrossRef Beasley GM, Ross MI, Tyler DS. Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia. 2008;24:301–9.PubMedCrossRef
36.
Zurück zum Zitat Wieberdink J. Physiological Considerations Regarding Isolation Perfusion of the Extremities. Meppel, The Netherlands: Krips Repro; 1978. Wieberdink J. Physiological Considerations Regarding Isolation Perfusion of the Extremities. Meppel, The Netherlands: Krips Repro; 1978.
37.
Zurück zum Zitat Vrouenraets BC, Kroon BB, van de Merwe SA, Klaase JM, Broekmeyer-Reurink MP, van Slooten GW, et al. Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: a pilot study. Eur Surg Res. 1996;28:235–44.PubMedCrossRef Vrouenraets BC, Kroon BB, van de Merwe SA, Klaase JM, Broekmeyer-Reurink MP, van Slooten GW, et al. Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: a pilot study. Eur Surg Res. 1996;28:235–44.PubMedCrossRef
38.
Zurück zum Zitat Thompson JF, Good PD, Kam PC. Hyperthermic isolated limb perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat. 1994;1:147–54. Thompson JF, Good PD, Kam PC. Hyperthermic isolated limb perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat. 1994;1:147–54.
39.
Zurück zum Zitat Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ryan RF, Creech O Jr. Regional chemotherapy for melanoma A 35-year experience. Ann Surg. 1994;220:520–35.PubMedCrossRef Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ryan RF, Creech O Jr. Regional chemotherapy for melanoma A 35-year experience. Ann Surg. 1994;220:520–35.PubMedCrossRef
40.
Zurück zum Zitat Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BBR. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:968–74.PubMed Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BBR. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:968–74.PubMed
41.
Zurück zum Zitat McMasters KM. Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:939–40,PubMedCrossRef McMasters KM. Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:939–40,PubMedCrossRef
42.
Zurück zum Zitat Vrouenraets BC, Kroon BB, Klaase JM, Bonfrer JM, Nieweg OE, van Slooten GW, et al. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol. 1997;4:88–94.PubMedCrossRef Vrouenraets BC, Kroon BB, Klaase JM, Bonfrer JM, Nieweg OE, van Slooten GW, et al. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol. 1997;4:88–94.PubMedCrossRef
43.
Zurück zum Zitat Sonneveld EJ, Vrouenraets BC, van Geel BN, Eggermont AM, Klaase JM, Nieweg OE, et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol. 1996;22:521–27.PubMedCrossRef Sonneveld EJ, Vrouenraets BC, van Geel BN, Eggermont AM, Klaase JM, Nieweg OE, et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol. 1996;22:521–27.PubMedCrossRef
44.
Zurück zum Zitat Thompson JF, Malouf DJ, Merzliakov S, Kam PC. Efficacy of singledose ondansetron in the prevention of post-operative nausea and vomiting following isolated limb perfusion with cytostatic agents. Reg Cancer Treat. 1993;4:177–82. Thompson JF, Malouf DJ, Merzliakov S, Kam PC. Efficacy of singledose ondansetron in the prevention of post-operative nausea and vomiting following isolated limb perfusion with cytostatic agents. Reg Cancer Treat. 1993;4:177–82.
Metadaten
Titel
Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients
verfasst von
Hidde M. Kroon, MD
Marc Moncrieff, MD, FCRS
Peter C. A. Kam, MD, FRCA, FANZCA
John F. Thompson, MD, FRACS, FACS
Publikationsdatum
01.05.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0323-x

Weitere Artikel der Ausgabe 5/2009

Annals of Surgical Oncology 5/2009 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.